Drugs / Equine ATG
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00582816 Background | Aug 2008 → Aug 2015 | cancer, leukemia | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00176930 Background | Oct 2001 → Dec 2019 | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +3 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Equine ATG | “Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816 ↗ |
| Known as | ATGAM | “Equine ATG (ATGAM)” NCT00176930 ↗ |
| Route | Intravenous | “15 mg/kg IV” NCT00176930 ↗ |